ARTICLE | Emerging Company Profile

Gate: selective blockade of pathogenic protein secretion

Gate Bio emerged from stealth with a $60M series A and a small molecule platform for selective gating of protein secretion

November 2, 2023 9:10 PM UTC

Gate emerged from stealth Wednesday to develop small molecules that stop pathogenic proteins from being secreted, instead sending them to the cytoplasm for degradation.

Gate Biosience Inc. was founded in 2021 with seed funding to build out a platform to create “molecular gates.” The company emerged from stealth Nov. 1 with $60 million in series A funding led by Versant Ventures and a16z Bio + Health, with participation from Arch Venture Partners and GV...